[
Biochemical recurrence
Indeterminate findings
Positron emission tomography/computed tomography (PET/CT)
Prostate cancer
Prostate-specific membrane antigen (PSMA)
Zirconium-89 (89Zr)
Journal
Cancer imaging : the official publication of the International Cancer Imaging Society
ISSN: 1470-7330
Titre abrégé: Cancer Imaging
Pays: England
ID NLM: 101172931
Informations de publication
Date de publication:
22 Feb 2024
22 Feb 2024
Historique:
received:
04
10
2023
accepted:
07
02
2024
medline:
23
2
2024
pubmed:
23
2
2024
entrez:
23
2
2024
Statut:
epublish
Résumé
The state-of-the-art method for imaging men with biochemical recurrence of prostate cancer (BCR) is prostate-specific membrane antigen (PSMA)-targeted positron emission tomography/computed tomography (PET/CT) with tracers containing short-lived radionuclides, e.g., gallium-68 ( To assess the ability of [ Altogether, 6/20 previously-indeterminate lesions (30%) were classified as suspicious (positive) for prostate cancer, 14/20 (70%), as non-suspicious (negative). In these two categories, [ In men with BCR, [ Not applicable.
Sections du résumé
BACKGROUND
BACKGROUND
The state-of-the-art method for imaging men with biochemical recurrence of prostate cancer (BCR) is prostate-specific membrane antigen (PSMA)-targeted positron emission tomography/computed tomography (PET/CT) with tracers containing short-lived radionuclides, e.g., gallium-68 (
METHODS
METHODS
To assess the ability of [
RESULTS
RESULTS
Altogether, 6/20 previously-indeterminate lesions (30%) were classified as suspicious (positive) for prostate cancer, 14/20 (70%), as non-suspicious (negative). In these two categories, [
CONCLUSIONS
CONCLUSIONS
In men with BCR, [
TRIAL REGISTRATION
BACKGROUND
Not applicable.
Identifiants
pubmed: 38389092
doi: 10.1186/s40644-024-00671-1
pii: 10.1186/s40644-024-00671-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
27Informations de copyright
© 2024. The Author(s).
Références
Afshar-Oromieh A, da Cunha ML, Wagner J, Haberkorn U, Debus N, Weber W, et al. Performance of [
doi: 10.1007/s00259-021-05189-3
pubmed: 33543325
pmcid: 8263399
Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466–86.
doi: 10.1007/s00259-022-06089-w
pubmed: 36604326
pmcid: 10027805
Bagguley D, Ong S, Buteau JP, Koschel S, Dhiantravan N, Hofman MS, et al. Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer. Future Oncol. 2021;17(17):2225–41.
doi: 10.2217/fon-2020-1293
pubmed: 33724868
Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77(4):403–17.
doi: 10.1016/j.eururo.2019.01.049
pubmed: 30773328
Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with
Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D et al. Diagnostic performance of
Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. Randomized prospective phase III trial of
doi: 10.1186/s12885-018-5200-1
pubmed: 30616601
pmcid: 6322287
Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678–88.
doi: 10.1007/s00259-016-3573-4
pubmed: 27889802
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208–16.
doi: 10.1016/S0140-6736(20)30314-7
pubmed: 32209449
Grunig H, Maurer A, Thali Y, Kovacs Z, Strobel K, Burger IA, et al. Focal unspecific bone uptake on [
doi: 10.1007/s00259-021-05424-x
pubmed: 34120201
pmcid: 8566387
Prive BM, Derks YHW, Rosar F, Franssen GM, Peters SMB, Khreish F, et al.
doi: 10.1007/s00259-021-05661-0
pubmed: 34932154
Rosar F, Bartholoma M, Maus S, Prive BM, Khreish F, Franssen GM, et al.
doi: 10.1097/RLU.0000000000004108
pubmed: 35234197
Rosar F, Schaefer-Schuler A, Bartholoma M, Maus S, Petto S, Burgard C, et al. [
doi: 10.1007/s00259-022-05925-3
pubmed: 35930033
pmcid: 9606102
Rosar F, Khreish F, Marlowe RJ, Schaefer-Schuler A, Burgard C, Maus S et al. Detection efficacy of [
Vazquez SM, Endepols H, Fischer T, Tawadros SG, Hohberg M, Zimmermanns B, et al. Translational development of a Zr-89-labeled inhibitor of prostate-specific membrane antigen for PET imaging in prostate cancer. Mol Imaging Biol. 2022;24(1):115–25.
doi: 10.1007/s11307-021-01632-x
pubmed: 34370181
Dietlein F, Kobe C, Vazquez SM, Fischer T, Endepols H, Hohberg M, et al. An
doi: 10.2967/jnumed.121.262290
pubmed: 34326129
Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al.
doi: 10.1007/s00259-017-3670-z
pubmed: 28283702
Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol. 2022;40(29):3377–82.
doi: 10.1200/JCO.22.00644
pubmed: 36001857
pmcid: 10166371
von Deimling M, Rajwa P, Tilki D, Heidenreich A, Pallauf M, Bianchi A, et al. The current role of precision surgery in oligometastatic prostate cancer. ESMO Open. 2022;7(6):100597.
doi: 10.1016/j.esmoop.2022.100597
Berghen C, Joniau S, Ost P, Poels K, Everaerts W, Decaestecker K, et al. Progression-directed therapy for oligoprogression in castration-refractory prostate cancer. Eur Urol Oncol. 2021;4(2):305–9.
doi: 10.1016/j.euo.2019.08.012
pubmed: 31558422
Jadvar H, Abreu AL, Ballas LK, Quinn DI. Oligometastatic prostate cancer: current status and future challenges. J Nucl Med. 2022;63(11):1628–35.
doi: 10.2967/jnumed.121.263124
pubmed: 36319116
pmcid: 9635685
Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by pet/ct: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56(11):1697–705.
doi: 10.2967/jnumed.115.161299
pubmed: 26294298
Afshar-Oromieh A, Hetzheim H, Kubler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of
doi: 10.1007/s00259-016-3419-0
pubmed: 27260521
Sharma P, Watts A, Singh H. Comparison of internal dosimetry of
doi: 10.1097/RLU.0000000000004353
pubmed: 35961365
Yoon JK, Park BN, Ryu EK, An YS, Lee SJ. Current perspectives on
Pandit-Taskar N, O’Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, et al. Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014;89(11):2093–105.
doi: 10.1007/s00259-014-2830-7
Pandit-Taskar N, O’Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, et al. A phase I/II study for analytic validation of
doi: 10.1158/1078-0432.CCR-15-0552
pubmed: 26175541
pmcid: 4668231
Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O’Donoghue JA, et al. First-in-humans imaging with
doi: 10.2967/jnumed.119.229781
pubmed: 31586002
pmcid: 7198374